Bristol Myers Squibb Shares Fall After Mixed Trial Results for Lung Disease Drug
Shares of Bristol-Myers Squibb Company (BMY) slipped 3.05% to $57.31 during Monday trading following mixed outcomes from a pivotal study evaluating admilparant, an oral medication for a severe lung condition. The trial achieved its main goal at a lower 60 mg twice-a-day dosage, demonstrating better lung function after 52 weeks compared to placebo. However, the higher 120 mg twice-a-day dosage did not achieve statistical significance in slowing lung function decline.
The findings highlight both promise and challenges for the drugmaker in treating idiopathic pulmonary fibrosis, a damaging organ illness with few effective remedies. On a positive note, the pharmaceutical firm also reported encouraging interim data from another late-stage study. Its radiopharmaceutical candidate RYZ101 successfully extended progression-free survival in patients with a rare form of neuroendocrine cancer who had already failed prior lutetium-based therapies.
Looking ahead, the enterprise plans to consult regulatory agencies regarding potential approval applications while preparing full dataset presentations for upcoming scientific conferences. Investors will also be tracking a separate Phase 3 study evaluating admilparant across a wider group of lung scarring patients, which is scheduled to release findings in early 2027.
Key points
- Bristol-Myers Squibb stock fell 3.05% to $57.31 after posting mixed Phase 3 results for its oral lung drug admilparant.
- The 60 mg twice-daily dose met its primary goal for lung function at 52 weeks, but the 120 mg dose failed to show statistical significance.
- A separate trial for RYZ101 succeeded in patients with a rare neuroendocrine cancer, significantly prolonging progression-free survival.
- The company intends to confer with health regulators and anticipates data from another lung fibrosis study in early 2027.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Why did Bristol Myers Squibb stock fall today?
Shares declined after late-stage trial data for admilparant showed that only the lower dose significantly improved lung function, while the higher dose failed to achieve statistical significance.
What were the results of the admilparant IPF study?
The 60 mg twice-daily dose met its primary 52-week endpoint in measuring lung capacity improvement, but the 120 mg twice-daily dose did not reach statistical significance despite slowing function loss.
Did Bristol Myers Squibb report any positive trial news?
Yes, an interim analysis for its cancer drug RYZ101 showed a statistically significant improvement in time without disease worsening for patients with rare neuroendocrine tumors.